Can Altered Target Sites be Therapeutically Targeted?
Yes, the identification of altered target sites has paved the way for the development of targeted therapies. Drugs like imatinib (Gleevec) target the BCR-ABL fusion protein in chronic myeloid leukemia (CML), while trastuzumab (Herceptin) targets the HER2/neu receptor in certain breast cancers. These targeted therapies are designed to specifically inhibit the molecular abnormalities caused by altered target sites, thereby improving treatment outcomes.
